P40337 (VHL_HUMAN) Homo sapiens (Human)
von Hippel-Lindau disease tumor suppressor UniProtKBInterProSTRINGInteractive Modelling
213 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3);
4 identical sequences: Homo sapiens: A0A024R2F2; Pan troglodytes: K7BID8, A0A6D2WU70; Pan paniscus: A0A2R9B5S8
It is possible new templates exist for this target since these models were created.
Available Structures
110 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Structural basis of Cullin-2 RING E3 ligase regulation by the COP9 signalosome |
Heteromer P61201; P62877; Q13098; Q13617; Q15369; Q15370; Q15843; Q7L5N1; Q92905; Q99627; Q9BT78; Q9H9Q2; Q9UNS2; | 100 | ||||
| FAK Protac GSK215 in complex with FAK and pVHL:ElonginC:ElonginB |
Heteromer Q05397; Q15369; Q15370; | 100 | 1×7QB; 4×PEG; 14×EDO; 1×CA; | |||
| The complex structure of Cul2-VCB-Protac-Wee1 |
Heteromer P30291; P62877; Q13617; Q15369; Q15370; | 100 | 1×W6U; | |||
| Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with Aryl linker |
Heteromer P61964; Q15369; Q15370; | 100 | 10×SCN; 1×Q43; 4×EDO; 1×K; | |||
| Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #1) |
Heteromer P61964; Q15369; Q15370; | 100 | 15×SCN; 13×EDO; 1×P6G; 1×Q3X; | |||
| BRG1 bromodomain in complex with VBC via compound 17 |
Heteromer P51532; Q15369; Q15370; | 100 | 5×PO4; 1×GOL; 1×VLH; | |||
| Crystal structure of PROTAC 1 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:El… |
Heteromer P51531; Q15369; Q15370; | 100 | 1×FX8; 11×EDO; 1×FMT; | |||
| Structure of pVHL-elongin B-elongin C (VCB) in complex with hydroxylated-HIF-2alpha (523-542) in th… |
Heteromer Q15370; Q2KII4; Q99814; | 100 | 1×GOL; | |||
| PROTAC6 mediated complex of VHL:EloB:EloC and Bcl-xL |
Heteromer Q07817; Q15369; Q15370; | 100 | 1×QL8; 17×EDO; 9×GOL; 12×IOD; | |||
| Crystal structure of compound 6 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:… |
Heteromer P51531; Q15369; Q15370; | 100 | 1×IFF; | |||
| Crystal structure of HIF-2alpha-pVHL-elongin B-elongin C |
Heteromer Q15369; Q15370; Q99814; | 100 | ||||
| Crystal structure of VHL in complex with H313, a Helicon Polypeptide |
Heteromer Q15369; Q15370; | 100 | 1×WHL; | |||
| Structure of a HIF-1a-pVHL-ElonginB-ElonginC Complex |
Heteromer Q15369; Q15370; Q16665; | 100 | ||||
| Crystal structure of a hydroxylated HIF-1 alpha peptide bound to the pVHL/elongin-C/elongin-B compl… |
Heteromer Q15369; Q15370; Q16665; | 100 | 1×SO4; | |||
| Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with PEG linker (conformation #2) |
Heteromer P61964; Q15369; Q15370; | 100 | 5×SCN; 1×Q3X; 7×EDO; | |||
| CRYSTAL STRUCTURE OF AT7 IN COMPLEX WITH THE SECOND BROMODOMAIN OF HUMAN BRD4 AND PVHL:ELONGINC:ELO… |
Heteromer O60885; Q15369; Q15370; | 100 | 1×IZR; | |||
| pVHL:EloB:EloC in complex with (4-(1H-pyrrol-1-yl)phenyl)methanol |
Heteromer Q15369; Q15370; Q16665; | 100 | 1×SO4; 1×F4K; 1×GOL; | |||
| Crystal structure of PROTAC 2 in complex with the bromodomain of human SMARCA4 and pVHL:ElonginC:El… |
Heteromer P51532; Q15369; Q15370; | 100 | 1×FWZ; 1×DMS; | |||
| Structure of pVHL-elongin B-elongin C (VCB) in complex with hydroxylated-HIF-2alpha (523-542) in th… |
Heteromer Q15369; Q15370; Q99814; | 100 | 1×FMT; | |||
| Crystal structure of the complex between VHL, ElonginB, ElonginC, and compound 5 |
Heteromer Q15369; Q15370; | 100 | 3×EDO; 1×DMS; 1×CL; 1×A1ARP; | |||
| Crystal structure of PROTAC 5 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:El… |
Heteromer P51531; Q15369; Q15370; | 100 | 1×IEI; | |||
| Crystal Structure of ligand ACBi1 in complex with bromodomain of human Smarca2 and pVHL:ElonginC:El… |
Heteromer P51531; Q15369; Q15370; | 100 | 7×EDO; 4×NA; 2×PEG; 1×87A; | |||
| Crystal structure of pVHL:ElonginC:ElonginB complex bound to PROTAC JW48 |
Heteromer Q15369; Q15370; | 100 | 1×SYF; | |||
| Crystal structure of PROTAC 2 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:El… |
Heteromer P51531; Q15369; Q15370; | 100 | 8×EDO; 1×FWZ; 1×EPE; | |||
| Ternary complex between VCB, BRD4-BD2 and PROTAC 51 |
Heteromer O60885; Q15369; Q15370; | 100 | 1×QLX; | |||
| The PROTAC MZ1 in complex with the second bromodomain of Brd4 and pVHL:ElonginC:ElonginB |
Heteromer O60885; Q15369; Q15370; | 100 | 1×759; | |||
| SelDeg51 in complex with FKBP51FK1 domain and pVHL:EloB:EloC |
Heteromer Q13451; Q15369; Q15370; | 100 | 1×XZW; | |||
| Ternary complex between VCB, BRD4-BD2 and PROTAC 48 |
Heteromer O60885; Q15369; Q15370; | 100 | 1×QIY; | |||
| E3:PROTAC:target ternary complex structure (VCB/WH244/BCL-2) |
Heteromer P10415; Q15369; Q15370; | 100 | 1×YFH; | |||
| Crystal structure of macrocyclic PROTAC 1 in complex with the second bromodomain of human Brd4 and … |
Heteromer O60885; Q15369; Q15370; | 100 | 1×LFE; | |||
| Ubiquitin ligation to neosubstrate by a cullin-RING E3 ligase & Cdc34: NEDD8-CUL2-RBX1-ELOB/C-VHL-M… |
Heteromer O60885; P0CG48; P62877; Q13617; Q15369; Q15370; Q712K3; | 100 | 3×ZN; 1×SY8; 1×759; | |||
| Crystal structure of Protac MS33 in complex with the WD repeat-containing protein 5 and pVHL:Elongi… |
Heteromer P61964; Q15369; Q15370; | 100 | 4×SCN; 5×EDO; 1×VKA; 1×GOL; 1×NA; | |||
| von Hippel-Lindau protein-ElonginB-ElonginC complex, bound to Hif1- alpha peptide |
Heteromer Q15369; Q15370; Q16665; | 100 | 1×GOL; | |||
| Ternary complex of VHL/BRD4-BD1/Compound9 (4-(3,5-difluoropyridin-2-yl)-N-(11-(((S)-1-((2S,4R)-4-hy… |
Heteromer O60885; Q15369; Q15370; | 100 | 1×WEP; | |||
| VCB in complex with compound 27 |
Heteromer Q15369; Q15370; | 100 | 1×QF3; | |||
| Crystal Structure of compound 4 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB |
Heteromer P01116; Q15369; Q15370; | 100 | 1×X53; 1×GDP; 1×MG; | |||
| Crystal structure of EloBC-VHL-CDO1 complex bound to compound 8 molecular glue |
Heteromer Q15369; Q15370; Q16878; | 100 | 1×A1ACI; 1×CIT; 1×FE2; | |||
| Crystal structure of EloBC-VHL-CDO1 complex bound to compound 4 molecular glue |
Heteromer Q15369; Q15370; Q16878; | 100 | 1×3JF; 1×CIT; 1×FE2; | |||
| VHL/Elongin B/Elongin C complex with compound 155 |
Heteromer Q15369; Q15370; | 100 | 1×VL6; | |||
| Structure of VHL-EloB-EloC-Cul2 |
Heteromer Q13617; Q15369; Q15370; | 100 | ||||
| Structural basis of Cullin-2 RING E3 ligase regulation by the COP9 signalosome |
Heteromer P61201; P62877; Q03071; Q13098; Q13617; Q15370; Q7L5N1; Q92905; Q99627; Q9BT78; Q9H9Q2; Q9UNS2; | 100 | 1×ZN; | |||
| (NEDD8)-CRL2VHL-MZ1-Brd4BD2-Ub(G76S, K48C)-UBE2R1(C93K, S138C, C191S, C223S)-Ub |
Heteromer O60885; P0CG48; P49427; P62877; Q13617; Q15369; Q15370; Q15843; | 100 | 1×759; 3×ZN; | |||
| Ternary complex between VCB, BRD4-BD1 and PROTAC 48 |
Heteromer O60885; Q15369; Q15370; | 100 | 4×SO4; 6×EDO; 1×QIY; | |||
| pVHL:EloB:EloC in complex with modified HIF-1a CODD peptide containing (3R,4S)-3-fluoro-4-hydroxypr… |
Heteromer Q15369; Q15370; Q16665; | 100 | ||||
| Crystal structure of pVHL:EloB:EloC in complex with MP-1-21 |
Heteromer Q15369; Q15370; | 100 | 1×A1H9F; | |||
| Quaternary Complex of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC Homer |
Heteromer P61964; Q15369; Q15370; | 100 | 1×8KH; | |||
| Structure of human WDR5 and pVHL:ElonginC:ElonginB bound to PROTAC with C3 linker |
Heteromer P61964; Q15369; Q15370; | 100 | 1×Q3R; | |||
| VHL recognizes hydroxyproline in RIPK1 |
Heteromer Q13546; Q15369; Q15370; | 100 | ||||
| E3:PROTAC:target ternary complex structure (VCB/753b/BCL-xL) |
Heteromer Q07817; Q15369; Q15370; | 100 | 1×CAD; 2×GOL; 1×YF8; | |||
| Crystal structure of the VCB complex with compound 1. |
Heteromer Q15369; Q15370; | 100 | 1×WBN; 1×CL; | |||
| VCB in complex with compound 32 |
Heteromer Q15369; Q15370; | 100 | 1×QF7; | |||
| Co-crystal structure of Compound 11 in complex with the bromodomain of human SMARCA2 and pVHL:Elong… |
Heteromer P51531; Q15369; Q15370; | 100 | 1×GOL; 1×FWZ; | |||
| DNA-encoded library (DEL)-enabled discovery of proximity inducing small molecules |
Heteromer O60885; Q15369; Q15370; | 100 | 1×X5K; | |||
| Open non-crosslinked structure Brd4BD2-MZ1-(NEDD8)-CRL2VHL |
Heteromer O60885; P62877; Q13617; Q15369; Q15370; | 100 | 1×759; 3×ZN; | |||
| VCB in complex with compound 30 |
Heteromer Q15369; Q15370; | 100 | 1×QE0; | |||
| Crystal structure of the complex between VHL, ElonginB, ElonginC, and compound 5 |
Heteromer Q15369; Q15370; | 100.0 | 1×TFA; 1×PEG; 1×EDO; 1×ACT; | |||
| VCB in complex with compound 23 |
Heteromer Q15369; Q15370; | 100 | 1×QFR; | |||
| Crystal Structure of compound 3 in complex with KRAS G12V C118S GDP and pVHL:ElonginC:ElonginB |
Heteromer P01116; Q15369; Q15370; | 100 | 1×GDP; 1×X4R; 1×MG; | |||
| Crystal Structure of ligand ACBI3 in complex with KRAS G12D C118S GDP and pVHL:ElonginC:ElonginB co… |
Heteromer P01116; Q15369; Q15370; | 100 | 1×WYL; 1×GDP; 1×MG; | |||
| E3:PROTAC:target ternary complex structure (VCB/753b/BCL-2) |
Heteromer P10415; Q15369; Q15370; | 100 | 1×YF8; | |||
| Crystal structure of compound 10 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC… |
Heteromer P51531; Q15369; Q15370; | 100 | 7×IOD; 1×IFJ; | |||
| VCB in complex with compound 26 |
Heteromer Q15369; Q15370; | 100 | 1×QE9; | |||
| Crystal structure of pVHL:EloB:EloC in complex with MP-1-39 |
Heteromer Q15369; Q15370; | 100 | 1×A1H6O; | |||
| Crystal structure of Protac MS67 in complex with the WD repeat-containing protein 5 and pVHL:Elongi… |
Heteromer P61964; Q15369; Q15370; | 100 | 1×GOL; 1×X6M; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-N-((S)-1-(5-Fluoro-2-methoxy-4-(4-methylthiazol-5-yl)phenyl)… |
Heteromer Q15369; Q15370; | 100 | 4×VH3; | |||
| pVHL54-213-EloB-EloC complex_(2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol- 5-yl)acetyl)-N-(4-nitrobenzy… |
Heteromer Q15369; Q15370; | 100.0 | 1×GOL; 1×ZUN; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbu… |
Heteromer Q15369; Q15370; | 100 | 4×VYQ; | |||
| VCB in complex with compound 21 |
Heteromer Q15369; Q15370; | 100 | 1×QFF; | |||
| Co-crystal structure of Compound 1 in complex with the bromodomain of human SMARCA4 and pVHL:Elongi… |
Heteromer P51532; Q15369; Q15370; | 100 | 1×NA; 1×YHB; 1×PEG; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-y… |
Heteromer Q15369; Q15370; | 100.0 | 1×3JU; | |||
| pVHL:EloB:EloC in complex with VH298 |
Heteromer Q15369; Q15370; | 100 | 1×6Z3; | |||
| pVHL54-213-EloB-EloC complex _ (2S,4R)-N-((1,1'-biphenyl)-4-ylmethyl)- 4-hydroxy-1-(2-(3-methylisox… |
Heteromer Q15369; Q15370; | 100.0 | 1×TR0; | |||
| THE VHL-ELONGINC-ELONGINB STRUCTURE |
Heteromer Q15369; Q15370; | 100 | ||||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-acetylcyclopropanecarboxamido)-3,3-dimethylbutan… |
Heteromer Q15369; Q15370; | 100 | 1×9BN; | |||
| pVHL54-213-EloB-EloC complex _ methyl 4-(((2S,4R)-4-hydroxy-1-(2-(3- methylisoxazol-5-yl)acetyl)pyr… |
Heteromer Q15369; Q15370; | 100.0 | 1×ZTD; | |||
| pVHL-EloB-EloB-EloC complex_(2S,4R)-1-(2-chlorophenyl)carbonyl-N-[(4-chlorophenyl)methyl]-4-oxidany… |
Heteromer Q15369; Q15370; | 100.0 | 1×ACT; 1×UCK; | |||
| pVHL54-213-EloB-EloC complex_apo |
Heteromer Q15369; Q15370; | 100 | ||||
| pVHL54-213-EloB-EloC complex (4R)-4-HYDROXY-1-[(3-METHYLISOXAZOL-5-YL)ACETYL]-N-[4-(1,3-OXAZOL-5-YL… |
Heteromer Q15369; Q15370; | 100 | 1×L8B; | |||
| pVHL-ELOB-ELOC complex_(2S,4R)-1-(3-amino-2-methylbenzoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)ben… |
Heteromer Q15369; Q15370; | 100.0 | 1×TG0; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(cyclobutanecarboxamido)-3,3-dimethylbutanoyl)-4-hy… |
Heteromer Q15369; Q15370; | 100 | 1×9BH; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-4-hydroxy-1-((S)-2-(2-hydroxyacetamido)-3,3-dimethylbutanoyl… |
Heteromer Q15369; Q15370; | 100 | 1×9BT; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-acetamido-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-m… |
Heteromer Q15369; Q15370; | 100 | 1×3JF; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-3-phenylpropanamido)-3,3-dimethylb… |
Heteromer Q15369; Q15370; | 100 | 1×3JO; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-3,3-dimethyl-2-(oxetane-3-carboxamido)butanoyl)-4-hyd… |
Heteromer Q15369; Q15370; | 100 | 1×9B8; | |||
| von Hippel Lindau protein:ElonginB:ElonginC complex, in complex with (2S,4R)-1-ethanoyl-N-[[4-(1,3-… |
Heteromer Q15369; Q15370; | 100.0 | 1×X6C; 1×ACT; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)… |
Heteromer Q15369; Q15370; | 100 | 1×3JG; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methyloxazol-5-yl… |
Heteromer Q15369; Q15370; | 100 | 1×3JK; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(cyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-h… |
Heteromer Q15369; Q15370; | 100 | 1×9BW; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutan… |
Heteromer Q15369; Q15370; | 100 | 1×4YY; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-4-methylpentanamido)-3,3-dimethylb… |
Heteromer Q15369; Q15370; | 100 | 1×3JH; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-((S)-2-acetamido-3,3-dimethylbutanamido)-3,3-dimeth… |
Heteromer Q15369; Q15370; | 100 | 1×3JJ; | |||
| pVHL:EloB:EloC in complex with modified VH032 containing (3S,4S)-3-fluoro-4-hydroxyproline (ligand … |
Heteromer Q15369; Q15370; | 100 | 1×EXE; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-acetamidocyclopropanecarboxamido)-3,3-dimethylbu… |
Heteromer Q15369; Q15370; | 100 | 1×9BK; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((2S,4R)-1-acetyl-4-hydroxypyrrolidine-2-carbonyl)-4-hydro… |
Heteromer Q15369; Q15370; | 100 | 1×3JS; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-Acetamidopropanethioyl)-4-hydroxy-N-(4-(4-methylthi… |
Heteromer Q15369; Q15370; | 100 | 1×DV5; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(thiazol-5-yl)benzyl… |
Heteromer Q15369; Q15370; | 100 | 1×3JT; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-(3,3-dimethylbutanoyl)-4-hydroxy-N-(3-methyl-4-(thiazol-5-… |
Heteromer Q15369; Q15370; | 100 | 1×3JV; | |||
| pVHL:EloB:EloC in complex with modified VH032 containing (3R,4S)-3-fluoro-4-hydroxyproline (ligand … |
Heteromer Q15369; Q15370; | 100 | 1×EXH; | |||
| pVHL:EloB:EloC in complex with N-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carba… |
Heteromer Q15369; Q15370; | 100 | 1×DV8; | |||
| pVHL:EloB:EloC in complex with N-((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carba… |
Heteromer Q15369; Q15370; | 100 | 1×DV2; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-(1-Fluorocyclopropane-1-carboxamido)-3,3-dimethylbu… |
Heteromer Q15369; Q15370; | 100 | 1×VFO; | |||
| pVHL:EloB:EloC in complex with (2S,4R)-1-((S)-2-acetamidopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol… |
Heteromer Q15369; Q15370; | 100 | 1×9B5; | |||
| Ternary complex between VCB, BRD4-BD1 and PROTAC 49 |
Heteromer O60885; Q15369; Q15370; | 100 | 1×SO4; 1×QIK; | |||
| pVHL:EloB:EloC in complex with methyl 4H-furo[3,2-b]pyrrole-5-carboxylate |
Heteromer Q15369; Q15370; | 100.0 | 2×ACT; 1×F4E; | |||
| von Hippel Lindau protein:ElonginB:ElonginC complex, in complex with (2S,4R)-N-methyl-1-[2-(3-methy… |
Heteromer Q15369; Q15370; | 100.0 | 1×QD0; | |||
| pVHL:EloB:EloC in complex with 6-chlorothiochroman-4-one |
Heteromer Q15369; Q15370; | 100.0 | 1×F7B; 1×IPA; | |||
| pVHL:EloB:EloC complex, in complex with capped Hydroxyproline |
Heteromer Q15369; Q15370; | 100.0 | 3×ACT; 1×V6F; | |||
| pVHL:EloB:EloC in complex with (4-(1H-pyrrol-1-yl)phenyl)methanol |
Heteromer Q15369; Q15370; | 100.0 | ||||
| PROTAC-mediated complex of KRAS with VHL/Elongin-B/Elongin-C/Cullin-2/Rbx1 |
Heteromer P01116; P62877; Q13617; Q15369; Q15370; | 100 | 2×ZN; 1×GDP; 1×WYL; | |||
| Crystal structure of the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex |
Heteromer P62877; Q13617; Q15369; Q15370; | 100 | 3×ZN; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4wqo.1.A | monomer | 0.84 | 100.00 | |||
2 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 4wqo.1.A | monomer | 0.62 | 100.00 | |||
| Isoform 3 | 6r7f.1.I | monomer | 0.86 | 100.00 | |||